Status:

COMPLETED

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma

Lead Sponsor:

Mayo Clinic

Conditions:

Metastatic Adenoid Cystic Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This phase II trial tests whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful for detecting therapy re...

Detailed Description

PRIMARY OBJECTIVES: I. Evaluate the feasibility of serial Ga-68 PSMA PET/CT for response assessment in metastatic adenoid cystic carcinoma. II. Assess the correlation of PSMA PET/CT response assessm...

Eligibility Criteria

Inclusion

  • ≥ 18 years of age
  • Diagnosis of metastatic adenoid cystic carcinoma
  • Enrolled in protocol MC200708
  • Ability to tolerate a Ga68 PSMA PET/CT imaging study
  • Willingness to return for a second PSMA PET/CT scan in approximately 12-20 weeks from the baseline PET/CT
  • Ability to give appropriate consent or have an appropriate representative available to do so

Exclusion

  • Unable to undergo PET/CT scan
  • Not a participant in MC200708
  • \< 18 years of age
  • Persons who are pregnant or nursing
  • Persons unable to consent to the study

Key Trial Info

Start Date :

August 12 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 12 2025

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT06521775

Start Date

August 12 2024

End Date

August 12 2025

Last Update

September 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma | DecenTrialz